April 20, 2014 5:35 AM ET

Biotechnology

Company Overview of XTL Biopharmaceuticals Ltd.

Company Overview

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company’s lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combi...

Building G

Herzliya Business Park

85 Medinat Hayehudim Street

PO Box 4033

Herzliya,  46140

Israel

Founded in 1993

12 Employees

Phone:

972 9 955 7080

Fax:

972 9 951 9727

Key Executives for XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. does not have any Key Executives recorded.

XTL Biopharmaceuticals Ltd. Key Developments

XTL Biopharmaceuticals Ltd. Reports Consolidated Earnings Results for the Year Ended December 31, 2013

XTL Biopharmaceuticals Ltd. reported consolidated earnings results for the year ended December 31, 2013. For the year, the company reported revenues of $2,369,000 against $938,000 for the same period a year ago. Operating loss was $2,894,000 against $2,356,000 for the same period a year ago. Loss for the period attributable to equity holders of the company was $2,476,000 or $0.01 per basic and diluted share against $1,390,000 or $0.01 per basic and diluted share for the same period a year ago. Loss from investment in associate was $845,000 compared to earnings from investment in associate of $569,000 a year ago. The increased loss was due to an impairment charge on the intangible assets related to the InterCure investment.

XTL Biopharmaceuticals Ltd., Annual General Meeting, Mar 17, 2014

XTL Biopharmaceuticals Ltd., Annual General Meeting, Mar 17, 2014.

XTL Mulls Acquisitions

XTL Biopharmaceuticals Ltd. (TASE:XTLB) has filed a shelf registration in the amount of $12.64 million. XTL said, "Unless we indicate otherwise in a prospectus supplement accompanying this prospectus, we plan to use the net proceeds from the sale of the securities for working capital and other general corporate purposes, which include but are not limited to, financing possible acquisitions, working capital, capital expenditures, redeeming outstanding securities, expanding sales and marketing, and research and development."

Similar Private Companies By Industry

Company Name Region
Natural Compounds Middle East/Africa
Periness Ltd. Middle East/Africa
GeneArrest Ltd. Middle East/Africa
RZ Comparative Diagnostics Ltd Middle East/Africa
Ultimate BioTransfer Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 12, 2013
Proteologics Ltd.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XTL Biopharmaceuticals Ltd., please visit www.xtlbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.